Is peritoneal dialysis a suitable renal replacement therapy in autosomal dominant polycystic kidney disease?

Nature Clinical Practice Nephrology

Volumn 5, Issue 3, 2009, Pages 122-123

  Goffin, Eric ^a   Pirson, Yves ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Albumin; Autosomal dominant polycystic kidney disease; Peritoneal dialysis; Peritonitis; Survival

Indexed keywords

AUTOSOMAL DOMINANT DISORDER; FOLLOW UP; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY; KIDNEY POLYCYSTIC DISEASE; LIVER; LIVER POLYCYSTIC DISEASE; NEPHRECTOMY; NOTE; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SURVIVAL; TREATMENT OUTCOME;

EID: 61349094030     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph1037     Document Type: Note

References (7)

1. del Peso G et al. (2003) Risk factors for abdominal wall complications in peritoneal dialysis patients. Perit Dial Int 23: 249-254
2. Fletcher S et al. (1994) Increased incidence of hydrothorax complicating peritoneal dialysis in patients with adult polycystic kidney disease. Nephrol Dial Transplant 9: 832-833
3. Hadimeri H et al. (1998) CAPD in patients with autosomal dominant polycystic kidney disease. Perit Dial Int 18: 429-432
4. Pandya BK et al. (2004) A comparison of peritonitis in polycystic and non-polycystic patients on peritoneal dialysis. Perit Dial Int 24: 79-81
5. Kumar S et al. (2008) Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis. Kidney Int 74: 946-951
6. Pirson Y et al. (2002) Treatment of patients with hereditary and congenital disorders. In Optimal Strategies of Treatment for End-Stage Renal Failure, 205-208 (Ed. Jacobs C) Oxford: Oxford University Press
7. Abbott KC and Agodoa LY (2002) Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 57: 208-214